Product/Composition:- | Silodosin |
---|---|
Strength:- | 2 mg,4 mg and 8 mg |
Form:- | Tablet & capsule |
Reference Brands:- | |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Silodosin. is marketed under the brand name Urief and among others. Silodosin received its first marketing approval in Japan in May 2006,[12][11] under the brand name Urief, which is jointly marketed by Kissei Pharmaceutical and Daiichi Sankyo. Kissei licensed the US, Canadian, and Mexican rights for silodosin to Watson Pharmaceuticals (now Allergan) in 2004.[13] AbbVie absorbed Allergan in 2019. The FDA and Health Canada approved silodosin under the brand name Rapaflo in October 2008,[14][15] and January 2011,[3] respectively.
Silodosin offers targeted, fast-acting relief from the symptoms of benign prostatic hyperplasia (BPH). With high selectivity for alpha-1A adrenergic receptors in the prostate and bladder, it ensures improved urinary flow and reduced irritation, all while minimizing cardiovascular side effects. Trusted by urologists for its superior tolerability and once-daily convenience, Silodosin helps patients reclaim comfort and confidence.